XML 39 R34.htm IDEA: XBRL DOCUMENT v3.20.1

Acquisition of Prismic Pharmaceutical (Tables)

12 Months Ended

Dec. 31, 2019

Disclosure of detailed information about business combination [abstract]

Schedule of share options and warrants

	Share Options	Warrants
Grant date share price	$32.16	$32.16
Exercise Price	$2.61 - $17.89	$2.61 - $26.73
Expected dividend yield	—	—
Risk free interest rate	1.39% - 1.66%	1.41% - 1.52%
Expected life (years)	0.98—16.21	1.39—6.55
Annualized volatility	100%	100%

Schedule of identifiable assets acquired and liabilities assumed

		Fair value
		recongized on
		acquisition
		$
Cash		2,329
Prepaids		26,174
Intellectual Property		24,648,915
Trade and other payables		(1,867,250	)
Short-term notes		(195,475	)
Notes payable		(1,727,484	)
		20,887,209

X

- Definition

The disclosure of detailed information about Share Options and Warrants.

+ References

No definition available.

+ Details

Name:	huge_DisclosureOfDetailedInformationAboutShareOptionsAndWarrantsExplanatory
Namespace Prefix:	huge_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	ifrs-full_DisclosureOfBusinessCombinationsAbstract
Namespace Prefix:	ifrs-full_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The disclosure of detailed information about business combinations. [Refer: Business combinations [member]]

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Name IFRS
-Number 3
-IssueDate 2019-01-01
-Section Disclosures application of paragraphs 59 and 61
-URI http://eifrs.ifrs.org/eifrs/xifrs-link?type=IFRS&num=3&code=ifrs-tx-2019-en-r&doctype=Appendix&subtype=B&dita_xref=IFRS03_gB64-B67_TI
-URIDate 2019-03-27

+ Details

Name:	ifrs-full_DisclosureOfDetailedInformationAboutBusinessCombinationsExplanatory
Namespace Prefix:	ifrs-full_
Data Type:	nonnum:textBlockItemType
Balance Type:	na
Period Type:	duration